Eltrekibart + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Trial Timeline
Oct 23, 2023 → Aug 1, 2026
NCT ID
NCT06046729About Eltrekibart + Placebo
Eltrekibart + Placebo is a phase 2 stage product being developed by Eli Lilly for Hidradenitis Suppurativa. The current trial status is active. This product is registered under clinical trial identifier NCT06046729. Target conditions include Hidradenitis Suppurativa.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06046729 | Phase 2 | Active |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 52 |
| Placebo + Adalimumab | AbbVie | Approved | 85 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Lutikizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 52 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 52 |
| Anifrolumab | AstraZeneca | Phase 2 | 52 |